DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— CNBC's Michael Bloom - 2 Cory Kasimov - 1 Kasimov - 1 We've - 1 Neurocrine - 1 Mohit - 1 Bansal - 1 Takeda - 1
Top related locs:
— Wells Fargo U.S
Top related orgs:
Biosciences - 2 ISI - 1 Biotech - 1 P Biotech - 1 Moderna - 1 LSEG - 1 U.S . Food - 1 Drug Administration - 1

Search resuls for: "crinecerfont"


3 mentions found


☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
  + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."
Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —
☆ Wells Fargo becomes bullish on this biotech company
  + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +1 min
Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.
Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo
☆ Stocks making the biggest moves after hours: Box, MongoDB, Dave & Buster's and more
  + stars: | 2023-12-05 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
Box — The cloud company plummeted 11% after reporting fiscal third-quarter adjusted earnings of 36 cents per share on revenue of $261.5 million. This was lower than FactSet's analyst expectations of 38 cents per share on $262.4 million of revenue. MongoDB — The database stock shed 4% despite MongoDB beating analysts' expectations in its third-quarter earnings. The company's $167 million revenue was also above the forecast $164 million. Dave & Buster's — The stock slipped 3% after the company posted third-quarter revenue of $466.9 million, lower than analysts' forecast for $473 million, per LSEG.
Persons: Asana, Buster's, LSEG Organizations: LSEG, Biosciences, U.S . Food, Drug Administration, crinecerfont, Toll Locations: U.S
0 next >>
Total: 3